About US
Contact us
-
Hep C landscape shifts again as BMS combo nabs breakthrough tagGilead Sciences ($GILD) and AbbVie ($ABBV) caught a break for their hepatitis C treatments when the FDA rescinded breakthrough designations earlier this year for potential competitors being developed2015/5/21
-
ProPublica: Safety questions over GSK's Advair linger after years on the asthma throneU.S. regulators gave GlaxoSmithKline's ($GSK)Advairthe green light a decade and a half ago, paving the way for a long reign that saw the med grow to more than $8 billion in annual sales. But even afte2015/5/21
-
Relax, J&J--Eliquis may be surging, but Xarelto's safe for nowPfizer ($PFE) and Bristol-Myers Squibb's ($BMY) new-age anticoagulant,Eliquis, has been ramping up after a slow start, growing 2014 sales to $774 million from $146 million the year prior. But Johnson2015/5/19
-
Perrigo will talk tie-up if the price is right, CEO says--but Mylan has a ways to goPerrigo's ($PRGO) not opposed to striking a pact with Mylan ($MYL)--as long as the price is right. The bad news for its suitor, though, is that right now, it's nowhere close. As Perrigo CEO Joseph Pa2015/5/19
-
AbbVie nabs FDA's orphan drug tag for Humira in HSAbbVie ($ABBV) is working to lessen its reliance on blockbusterHumira, which is already facing biosimilar competition inIndia. But it's also working to broaden the drug's label, and on that front, it2015/5/18
-
Actavis talks to DOJ about resolving probe of Warner Chilcott marketing misdeedsActavis completed its buyout of Ireland'sWarner Chilcottmore than a year ago and is now trying to rid itself of some nasty legal entanglements that it picked up in the $8.5 billion deal. The drugmaker2015/5/18
-
Vertex eyes big revenue boost with FDA panel backing for OrkambiVertex Pharmaceuticals ($VRTX) wants to expand its cystic fibrosis market tenfold, and on Tuesday, it got one step closer. An FDA advisory committee voted 12 to 1 in favor of a new combo drug Orkambi,2015/5/14
-
Contrave controversy puts Orexigen, Takeda in unwelcome spotlightTheFDAwas none too happy with Orexigen ($OREX) when it put out some early positive cardio data for obesity drugContravein March. One reason? Early data can be misleading--and now, it looks like that m2015/5/14
-
Endo plots a double-sized salesforce, new DTC push for Stendra relaunchNot satisfied with the way its new purchase Auxilium had handled Stendra marketing, Endo ($ENDP) plans to relaunch the erectile dysfunction med, which it sells in partnership with Vivus ($VVUS). Endo2015/5/13
-
Baxter pads biopharma unit with pre-spinoff oncology buyAs Baxter ($BAX) gears up to spin off its biopharma unit into new companyBaxalta, it wants to make sure the new pharma has enough revenue to rely on. And to do that, it's bulking up. The Illinois com2015/5/13